Clinical Trials | December 20, 2022
Global pharmaceutical company having a surgical business concept incepted in Dubai
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
The investment will enable the company to enter European markets as well as enhance margins in current markets
The current ruling will assure the safety of the use of Ranitidine for Indian patients
EC grants conditional marketing authorization based on the EFFISAYIL trial
Subscribe To Our Newsletter & Stay Updated
